SPECIALTY GUIDELINE MANAGEMENT

CERDELGA (eliglustat)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers as detected by an FDA-cleared test.

Limitations of use: Patients who are CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of Cerdelga to achieve a therapeutic effect. A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).

All other indications are considered experimental/investigational and are not a covered benefit.

II. REQUIRED DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: beta-glucocerebrosidase enzyme assay or genetic testing results supporting diagnosis and the results of the CYP2D6 test.

III. CRITERIA FOR INITIAL APPROVAL

Gaucher disease type 1

Authorization of 12 months may be granted for treatment of Gaucher disease type 1 when all of the following criteria are met:

1. Diagnosis of Gaucher disease was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing
2. Member is a CYP2D6 extensive metabolizer, an intermediate metabolizer, or a poor metabolizer as detected by an FDA-cleared test

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for Gaucher disease type 1 who are not experiencing an inadequate response or any intolerable adverse events from therapy.

V. REFERENCES